Новый способ диагностики раннего субклинического поражения почек у больных гипертонической болезнью и возможности его коррекции в зависимости от тактики и выбора антигипертензивной терапии
https://doi.org/10.18705/1607-419X-2012-18-1-37-44
Аннотация
Об авторах
А. В. БушмакинаРоссия
Н. А. Козиолова
Россия
Н. А. Ковалевская
Россия
И. М. Шатунова
Россия
Список литературы
1. Mancia G., Backer G., Dominiczak A. et al. 2007 Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) // J. Hypertens. — 2007. — Vol. 25, № 6. — P. 1105-1187.
2. Cotter J., Oliveira P., Cunha P., Polonia J. Different patterns of one-year evolution of microalbuminuria in hypertensive patients treated with different inhibitors of the renin-angiotensin system // Rev. Port. Cardiol. — 2008. — Vol. 27, № 11. — Р. 1395-1404.
3. Brouwers F.P., Asselbergs F.W., Hillege H.L. et al. Long-term effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria: ten years of follow-up of Prevention of Renal and Vascular End-stage Disease Intervention Trial (PREVEND IT) // Am. Heart J. — 2011. — Vol. 161, № 6. — Р 1171-1178.
4. Ari E., Kaya Y., Demir H. et al. Oxidative DNA damage correlates with carotid artery atherosclerosis in hemodialysis patients // Hemodial. Int. — 2011. — Vol. 15, № 4. — Р. 453-459.
5. Dorman G., Cseh S., Hajdù I. et al. Matrix metalloproteinase inhibitors: a critical appraisal of design principles and proposed therapeutic utility // Drugs. — 2010. — Vol. 70, № 8. — Р 949-964.
6. Bauvois B. New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: Outside-in signaling and relationship to tumor progression // Biochim. Biophys. Acta. — 2012. — Vol. 1825, № 1. — Р. 29-36.
7. Romi F., Helgeland G., Gilhus N.E. Serum levels of matrix metal-loproteinases: implications in clinical neurology // Eur. Neurol. — 2012. — Vol. 67, № 2. — Р. 121-128.
8. Saglam F., Celik A., Tayfur D. et al. Decrease in cell proliferation by an matrix metalloproteinase inhibitor, doxycycline, in a model of immune-complex nephritis // Nephrology (Carlton). — 2010. — Vol. 15, № 5. — Р. 560-567.
9. Chung A.W., Yang H.H., Kim J.M. et al. Upregulation of matrix metalloproteinase-2 in the arterial vasculature contributes to stiffening and vasomotor dysfunction in patients with chronic kidney disease // Circulation. — 2009. — Vol. 120, № 9. — Р 792-801.
10. Fang J.H., Zhou H.C., Zeng C. et al. MicroRNA-29b suppresses tumor angiogenesis, invasion, and metastasis by regulating matrix metal-loproteinase 2 expression // Hepatology. — 2011. — Vol. 54, № 5. — Р. 1729-1740.
11. Klein J., Kavvadas P., Prakoura N. et al. Renal fibrosis: insight from proteomics in animal models and human disease // Proteomics. — 2011. — Vol. 11, № 4. — Р. 805-815.
12. Choi D.E., Jeong J.Y., Lim B.J. et al. Aliskiren ameliorates renal inflammation and fibrosis induced by unilateral ureteral obstruction in mice // J. Urol. — 2011. — Vol. 186, № 2. — Р. 694-701.
13. Mathew A., Cunard R., Sharma K. Antifibrotic treatment and other new strategies for improving renal outcomes // Contrib. Nephrol. — 2011. — Vol. 170. — P. 217-227.
14. Saglam M., Karakaya O., Esen A.M. et al. Contribution of plasma matrix metalloproteinases to development of left ventricular hypertrophy and diastolic dysfunction in hypertensive subjects // Tohoku J. Exp. Med. — 2006. — Vol. 208, № 2. — Р. 117-122.
15. Cornish T.C., Bagnasco S.M., Macgregor A.M. et al. Glomerular protein levels of matrix metalloproteinase-1 and tissue inhibitor of metal-loproteinase-1 are lower in diabetic subjects // J. Histochem. Cytochem. — 2009. — Vol. 57, № 11. — Р. 995-1001.
16. Spiers J.P., Kelso E.J., Siah W.F. et al. Alterations in vascular matrix metalloproteinase due to ageing and chronic hypertension: effects of endothelin receptor blockade // J. Hypertens. — 2005. — Vol. 23, № 9. — Р. 1717-1724.
17. Castro M.M., Rizzi E., Prado C.M. et al. Imbalance between matrix metalloproteinases and tissue inhibitor of metalloproteinases in hypertensive vascular remodeling // Matrix Biol. — 2010. — Vol. 29, № 3. — Р. 194-201.
18. Lim C.S., Shalhoub J., Gohel M.S. et al. Matrix metalloproteinases in vascular disease-a potential therapeutic target? // Curr. Vasc. Pharmacol. — 2010. — Vol. 8, № 1. — Р. 75-85.
19. Kelly D., Squire I.B., Khan S.Q. et al. Usefulness of plasma tissue inhibitors of metalloproteinases as markers of prognosis after acute myocardial infarction // Am. J. Cardiol. — 2010. — Vol. 106, № 4. — Р. 477-482.
20. Castro M.M., Tanus-Santos J.E., Gerlach R.F. Matrix metallo-proteinases: targets for doxycycline to prevent the vascular alterations of hypertension // Pharmacol. Res. — 2011. — Vol. 64, № 6. — P. 567-572.
21. Marçal D.M., Rizzi E., Martins-Oliveira A. et al. Comparative study on antioxidant effects and vascular matrix metalloproteinase-2 downregulation by dihydropyridines in renovascular hypertension // Naunyn Schmiedebergs Arch. Pharmacol. — 2011. — Vol. 383, № 1. — Р. 35-44.
22. Cheng X., Zhou Q., Lin S., Wu R. Fosinopril and valsartan intervention in gene expression of Klotho, MMP-9, TIMP-1, and PAI-1 in the kidney of spontaneously hypertensive rats // Zhong Nan Da Xue Xue Bao Yi Xue Ban. — 2010. — Vol. 35, № 10. — Р. 1048-1056.
23. Tayebjee M.H., Nadar S., Blann A.D. et al. Matrix metallopro-teinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) // Am. J. Hypertens. — 2004. — Vol. 17, № 9. — Р. 764-769.
24. Yamamoto D., Takai S. Pharmacological implications of MMP-9 inhibition by ACE inhibitors // Curr. Med. Chem. — 2009. — Vol. 16, № 11. — Р. 1349-1354.
25. Cheng X.W., Song H., Sasaki T. et al. Angiotensin type 1 receptor blocker reduces intimal neovascularization and plaque growth in apolipoprotein E-deficient mice // Hypertension. — 2011. — Vol. 57, № 5. — Р. 981-989.
26. Onal I.K., Altun B., Onal E.D. et al. Serum levels of MMP-9 and TIMP-1 in primary hypertension and effect of antihypertensive treatment // Eur. J. Intern. Med. — 2009. — Vol. 20, № 4. — Р. 369-372.
27. Marchesi C., Dentali F., Nicolini E. et al. Plasma levels of matrix metalloproteinases and their inhibitors in hypertension: a systematic review and meta-analysis // J. Hypertens. — 2012. — Vol. 30, № 1. — Р. 3-16.
28. Schroeder K., Fahey T., Hay A.D. et al. Relationship between medication adherence and blood pressure in primary care: prospective study // J. Hum. Hypertens. — 2006. — Vol. 20, № 8. — Р. 625-627.
29. Slavachevsky I., Rachmani R., Levi Z. et al. Effect of enalapril and nifedipine on orthostatic hypotension in older hypertensive patients // J. Am. Geriatr. Soc. — 2000. — Vol. 48, № 7. — Р. 807-810.
30. Schrader J., Lüders S., Kulschewski A. et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES) // Stroke. — 2005. — Vol. 36, № 6. — Р. 1218-1226.
31. Mann J.F., Schmieder R.E., McQueen M. et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial // Lancet. — 2008. — Vol. 372, № 9638. — Р. 547-553.
32. Vase H., Lauridsen T.G., Graffe C.C., Pedersen E.B. The effect of eprosartan on reflex sympathetic activation in sodium restricted patients with essential hypertension // J. Am. Soc. Hypertens. — 2011. — Vol. 5, № 5. — Р. 385-394.
Рецензия
Для цитирования:
Бушмакина А.В., Козиолова Н.А., Ковалевская Н.А., Шатунова И.М. Новый способ диагностики раннего субклинического поражения почек у больных гипертонической болезнью и возможности его коррекции в зависимости от тактики и выбора антигипертензивной терапии. Артериальная гипертензия. 2012;18(1):37-44. https://doi.org/10.18705/1607-419X-2012-18-1-37-44
For citation:
Bushmakina A.V., Koziolova N.A., Kovalevskaya N.A., Shatunova I.M. A new method of diagnostics of early subclinical renal damage in hypertensive patients: The potential benefits of various therapeutic approaches. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2012;18(1):37-44. (In Russ.) https://doi.org/10.18705/1607-419X-2012-18-1-37-44